Identifying new blood tests for early lung cancer detection
Developing Novel Circulating Epigenetic Biomarkers for Early Detection of Lung Cancer
This study is testing new blood tests to see if they can help find lung cancer early by looking for specific markers in the blood.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 900 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT04814407 on ClinicalTrials.gov |
What this trial studies
This study aims to discover novel circulating methylated biomarkers that can be used for the early detection of lung cancer. By analyzing cell-free tumor DNA (ctDNA) and the methylation patterns of T cells, the researchers hope to develop highly sensitive and specific blood-based assays. The study will compare the genetic profiles of lung cancer patients with non-cancer subjects to identify potential early indicators of malignancy. This approach offers a non-invasive alternative to traditional biopsy methods, which can be limited in sensitivity and specificity.
Who should consider this trial
Good fit: Ideal candidates include individuals suspected or confirmed to have lung cancer, as well as those with indeterminate pulmonary nodules or chronic inflammatory airway diseases.
Not a fit: Patients who are pregnant, have HIV infection, or are unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier and more accurate detection of lung cancer, improving treatment outcomes for patients.
How similar studies have performed: Other studies have shown promise in using ctDNA and methylation patterns for cancer detection, indicating that this approach may be viable.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects suspected or confirmed diagnosis of lung cancer. * Subjects who had indeterminate sub-centimeter pulmonary nodules or ground glass opacities discovered by computed tomography. * Non-cancer subjects: including healthy volunteers and chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc. * Subjects age over 20. Exclusion Criteria: * Pregnancy. * Subjects with HIV infection. * Unable to or unwilling to give informed consent.
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Hsing-Chen Tsai, M.D., Ph.D
- Email: htsai@ntu.edu.tw
- Phone: +886-2-23123456
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.